Dato-DXd Filing Lifts Mood For AstraZeneca Investors
AstraZeneca and Daiichi-Sankyo are targeting only non-squamous patients with their first Dato-DXd filing, but are still on course for a first-in-class approval by year end.
AstraZeneca and Daiichi-Sankyo are targeting only non-squamous patients with their first Dato-DXd filing, but are still on course for a first-in-class approval by year end.